TWI798228B - 固定劑量調配物 - Google Patents

固定劑量調配物 Download PDF

Info

Publication number
TWI798228B
TWI798228B TW107118013A TW107118013A TWI798228B TW I798228 B TWI798228 B TW I798228B TW 107118013 A TW107118013 A TW 107118013A TW 107118013 A TW107118013 A TW 107118013A TW I798228 B TWI798228 B TW I798228B
Authority
TW
Taiwan
Prior art keywords
acid
bempedelic
ezetimibe
composition
weight
Prior art date
Application number
TW107118013A
Other languages
English (en)
Chinese (zh)
Other versions
TW201900154A (zh
Inventor
穆罕默德 阿布達爾奈紗
普拉提哈 S 皮爾高克
安尼庫瑪 S 甘地
Original Assignee
美商伊斯比瑞恩治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商伊斯比瑞恩治療公司 filed Critical 美商伊斯比瑞恩治療公司
Publication of TW201900154A publication Critical patent/TW201900154A/zh
Application granted granted Critical
Publication of TWI798228B publication Critical patent/TWI798228B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW107118013A 2017-05-26 2018-05-25 固定劑量調配物 TWI798228B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762511889P 2017-05-26 2017-05-26
US62/511,889 2017-05-26
US15/859,279 US20180338922A1 (en) 2017-05-26 2017-12-29 Fixed dose formulations
US15/859,279 2017-12-29

Publications (2)

Publication Number Publication Date
TW201900154A TW201900154A (zh) 2019-01-01
TWI798228B true TWI798228B (zh) 2023-04-11

Family

ID=62621055

Family Applications (2)

Application Number Title Priority Date Filing Date
TW107118013A TWI798228B (zh) 2017-05-26 2018-05-25 固定劑量調配物
TW112108490A TWI921644B (zh) 2017-05-26 2018-05-25 固定劑量調配物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW112108490A TWI921644B (zh) 2017-05-26 2018-05-25 固定劑量調配物

Country Status (16)

Country Link
US (2) US20180338922A1 (cg-RX-API-DMAC7.html)
EP (1) EP3630070A1 (cg-RX-API-DMAC7.html)
JP (3) JP7187488B2 (cg-RX-API-DMAC7.html)
KR (3) KR102830720B1 (cg-RX-API-DMAC7.html)
CN (1) CN110996914A (cg-RX-API-DMAC7.html)
AU (2) AU2018272040A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019024747A2 (cg-RX-API-DMAC7.html)
CA (1) CA3064895A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019003437A1 (cg-RX-API-DMAC7.html)
IL (2) IL270866B2 (cg-RX-API-DMAC7.html)
MX (2) MX2019014122A (cg-RX-API-DMAC7.html)
PH (1) PH12019502782A1 (cg-RX-API-DMAC7.html)
TW (2) TWI798228B (cg-RX-API-DMAC7.html)
UA (1) UA126451C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018218147A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201908030B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392182B (es) 2015-03-13 2025-03-21 Esperion Therapeutics Inc Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
EP3752133A1 (en) * 2018-02-16 2020-12-23 Esperion Therapeutics, Inc. Sustained release formulations of bempedoic acid
WO2020046836A1 (en) * 2018-08-27 2020-03-05 Esperion Therapeutics, Inc. Combination drug formulations for treating patients with cardiovascular disease and associated conditions
EP3666750A1 (en) * 2018-12-10 2020-06-17 Sandoz AG Crystalline form of bempedoic acid
WO2020213010A1 (en) * 2019-04-16 2020-10-22 Celagenex Research (India) Pvt. Ltd. Synergistic lipid controlling compositions
CN112437765A (zh) * 2019-06-21 2021-03-02 艾斯柏伦治疗公司 贝派地酸的盐形式及其使用方法
US12528759B2 (en) 2019-10-03 2026-01-20 Synthon B.V. Crystalline forms of bempedoic acid
EP4069668A1 (en) 2019-12-06 2022-10-12 Synthon B.V. Crystalline forms of sodium salt of bempedoic acid
US20230149313A1 (en) * 2020-04-10 2023-05-18 Japan Vam & Poval Co., Ltd. Sustained-release base
WO2021220236A1 (en) * 2020-05-01 2021-11-04 Cadila Healthcare Limited Pharmaceutical compositions for combination therapy
CN111559961A (zh) * 2020-05-26 2020-08-21 杭州科巢生物科技有限公司 一种贝派地酸晶型及其制备方法
WO2021255180A1 (en) 2020-06-19 2021-12-23 Synthon B.V. Salts of bempedoic acid
EP4401708A1 (en) 2021-09-13 2024-07-24 Synthon B.V. Pharmaceutical composition of bempedoic acid
US20250302750A1 (en) * 2022-05-09 2025-10-02 Renata Pharmaceuticals (Ireland) Ltd Pharmaceutical composition of bempedoic acid
JP7877242B2 (ja) * 2023-02-16 2026-06-22 株式会社三共 遊技機
JP7877241B2 (ja) * 2023-02-16 2026-06-22 株式会社三共 遊技機
WO2026125708A1 (en) 2024-12-12 2026-06-18 Krka, D.D., Novo Mesto Tablets comprising bempedoic acid or bempedoic acid and ezetimibe

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100234342A1 (en) * 2009-03-13 2010-09-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Ezetimibe compositions
WO2017079755A1 (en) * 2015-11-06 2017-05-11 Gemphire Therapeutics Inc. Gemcabene combinations for the treatment of cardiovascular disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
JP4438268B2 (ja) * 2001-03-07 2010-03-24 大日本住友製薬株式会社 薬物顆粒の製造方法、および薬物顆粒、ならびにそれを用いた医薬製剤
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7335689B2 (en) 2003-01-23 2008-02-26 Esperion Therapeutics, Inc. Dihydroxyl compounds and compositions for cholesterol management and related uses
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
EP2168573A1 (en) * 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
PL2407166T3 (pl) * 2009-03-13 2014-01-31 Toyama Chemical Co Ltd Tabletka i granulowany proszek zawierające 6-fluoro-3-hydroksy-2-pirazynokarboksamid
PL2459175T3 (pl) * 2009-07-28 2018-04-30 Egis Gyógyszergyár Zrt. Nowy proces granulowania i otrzymany w ten sposób granulat
CN101926756B (zh) * 2010-08-12 2012-01-18 北京赛科药业有限责任公司 一种氯吡格雷或其药学上可接受盐的固体制剂
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
AR086675A1 (es) * 2011-06-14 2014-01-15 Merck Sharp & Dohme Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
US10137093B2 (en) * 2011-08-16 2018-11-27 Cardiora Pty Ltd. Milrinone controlled-release formulation
CA2933202C (en) * 2014-01-21 2022-05-31 Jason Teckoe Immediate release film coatings containing medium chain glycerides and substrates coated therewith
MX392182B (es) * 2015-03-13 2025-03-21 Esperion Therapeutics Inc Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2017023165A1 (en) 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100234342A1 (en) * 2009-03-13 2010-09-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Ezetimibe compositions
WO2017079755A1 (en) * 2015-11-06 2017-05-11 Gemphire Therapeutics Inc. Gemcabene combinations for the treatment of cardiovascular disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Peter Penson Expert Opinion on Investigational Drugs Volume 26, 2017 - Issue 2 Published online: 17 Jan 2017 Pages 251-259 *

Also Published As

Publication number Publication date
IL270866B2 (en) 2025-07-01
US20220249380A1 (en) 2022-08-11
KR20240130156A (ko) 2024-08-28
US20180338922A1 (en) 2018-11-29
PH12019502782A1 (en) 2020-10-26
IL270866B1 (en) 2025-03-01
JP7561814B2 (ja) 2024-10-04
UA126451C2 (uk) 2022-10-05
CN110996914A (zh) 2020-04-10
RU2019142143A3 (cg-RX-API-DMAC7.html) 2021-07-19
TW202400126A (zh) 2024-01-01
JP2020521763A (ja) 2020-07-27
KR20200032044A (ko) 2020-03-25
KR102830720B1 (ko) 2025-07-08
JP2024178341A (ja) 2024-12-24
TWI921644B (zh) 2026-04-11
AU2024204369B2 (en) 2025-09-11
BR112019024747A2 (pt) 2020-06-09
TW201900154A (zh) 2019-01-01
MX2023006541A (es) 2023-06-16
KR20250109242A (ko) 2025-07-16
AU2018272040A1 (en) 2019-12-19
IL318957A (en) 2025-04-01
MX2019014122A (es) 2020-02-07
RU2019142143A (ru) 2021-06-28
CA3064895A1 (en) 2018-11-29
EP3630070A1 (en) 2020-04-08
AU2024204369A1 (en) 2024-07-11
CL2019003437A1 (es) 2020-07-10
JP7187488B2 (ja) 2022-12-12
ZA201908030B (en) 2026-04-29
WO2018218147A1 (en) 2018-11-29
JP2023022224A (ja) 2023-02-14
IL270866A (en) 2020-01-30
KR102698987B1 (ko) 2024-08-28

Similar Documents

Publication Publication Date Title
JP7561814B2 (ja) 固定用量製剤
ES2325764T3 (es) Preparaciones orales con buenas caracteristicas de desintegracion.
CN103998037B (zh) 对高熔点疏水性化合物具有改进的生物利用度的药物组合物
KR20130122019A (ko) 약학 조성물
AU2008309385B2 (en) Zibotentan composition containing mannitol and/or microcrystalline cellulose
TW201117838A (en) (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
US20250281413A1 (en) Pharmaceutical composition
US9572806B2 (en) Elution-stabilized preparation
EP2726064B1 (en) Controlled release oral dosage form comprising oxycodone
CN100479808C (zh) 贝特类片剂及其制备方法
RU2810163C2 (ru) Составы в фиксированных дозах
HK40020442A (en) Fixed dose formulations
WO2024085821A1 (en) Content uniformity of teriflunomid in pharmaceutical dosage forms
JP2025065015A (ja) 安定性が改善されたセレコキシブ-アセトアミノフェン配合剤およびその調製方法
Maincent Modified release formulations manufactured by hot-melt extrusion
PAUL MASTER OF PHARMACY
Lokesha Design and In-Vitro Evaluation of Fast Disintegrating Tablets of an Antihypertensive Drug